Iterative experimental testing of these targets and feedback from the PMC and CRP will identify novel pathways in psoriasis pathogenesis that are likely to benefit from intervention by new or ...

"In recent years, highly effective drugs have become available for treating psoriasis, particularly those that block ...

Neutrophils are also involved in the pathogenesis of psoriasis through their interactions with other immune cells and keratinocytes. Furthermore, studies have identified high levels of iron in the ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Blood dendritic cell antigen 2 (BDCA2) is expressed in plasmacytoid dendritic cells. These cells’ overproduction of type I interferon is closely linked to the pathogenesis of systemic lupus ...

Decades ago, psoriasis was thought to be driven by the ... from human subjects taken at different times during the disease pathogenesis. The accessibility of the skin permits the use of many ...

2009.0011 Key words: psoriasis, treatment concept, genetics, immune-mediated inflammatory disease, guidelines Recent scientific advances have led to new concepts of the pathogenesis of psoriasis ...

Over the past three decades, laboratory and clinical research findings have shown that T cells are the primary mediators of psoriasis pathogenesis and that psoriasis can be treated by eliminating ...

Psoriasis is a chronic skin disorder characterized ... target T cells that are involved in disease pathogenesis, but have been niche agents owing to modest efficacy. Efalizumab was recently ...